DE69735191D1 - Verfahren zur Herstellung multivalenter Impfstoffe - Google Patents

Verfahren zur Herstellung multivalenter Impfstoffe

Info

Publication number
DE69735191D1
DE69735191D1 DE69735191T DE69735191T DE69735191D1 DE 69735191 D1 DE69735191 D1 DE 69735191D1 DE 69735191 T DE69735191 T DE 69735191T DE 69735191 T DE69735191 T DE 69735191T DE 69735191 D1 DE69735191 D1 DE 69735191D1
Authority
DE
Germany
Prior art keywords
vaccine
components
component
composition
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735191T
Other languages
English (en)
Other versions
DE69735191T2 (de
Inventor
Franupsilonois Arminjon
Jean-Renomega Cartier
Sandrine Lentsch-Graf
Laurent Marchal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur MSD SNC
Original Assignee
Aventis Pasteur MSD SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur MSD SNC filed Critical Aventis Pasteur MSD SNC
Application granted granted Critical
Publication of DE69735191D1 publication Critical patent/DE69735191D1/de
Publication of DE69735191T2 publication Critical patent/DE69735191T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69735191T 1997-09-15 1997-09-15 Verfahren zur Herstellung multivalenter Impfstoffe Expired - Lifetime DE69735191T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/005378 WO1999013906A1 (en) 1997-09-15 1997-09-15 Multivalent vaccines

Publications (2)

Publication Number Publication Date
DE69735191D1 true DE69735191D1 (de) 2006-04-13
DE69735191T2 DE69735191T2 (de) 2006-10-05

Family

ID=8166750

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735191T Expired - Lifetime DE69735191T2 (de) 1997-09-15 1997-09-15 Verfahren zur Herstellung multivalenter Impfstoffe

Country Status (10)

Country Link
EP (1) EP1028750B1 (de)
AT (1) ATE316797T1 (de)
AU (1) AU4707097A (de)
BR (1) BR9714980A (de)
CA (1) CA2303105A1 (de)
DE (1) DE69735191T2 (de)
DK (1) DK1028750T3 (de)
ES (1) ES2257769T3 (de)
PT (1) PT1028750E (de)
WO (1) WO1999013906A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004314A1 (de) * 1998-11-26 2000-05-31 Pasteur Merieux MSD T.d.Polio Impstoff für einer primovakzinierter oder empfindlicher Population
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2783274C (en) * 2000-06-29 2018-08-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition with reduced dose of haemophilus influenza type b
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
WO2004039417A2 (en) * 2002-11-01 2004-05-13 Glaxosmithkline Biologicals S.A. Drying process
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
MX2007016403A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
US8124397B2 (en) 2005-08-08 2012-02-28 Oregon Health & Science University Inactivating pathogens with oxidizing agents for vaccine production
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
RU2705163C2 (ru) 2011-01-05 2019-11-05 Бхарат Байотек Интернэшнл Лимитед Комбинированная семивалентная вакцина
FR2985663B1 (fr) 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
KR20150065878A (ko) * 2012-10-12 2015-06-15 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 백신에서 사용하기 위한 가교되지 않은 무세포 백일해 항원
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN105646726A (zh) * 2016-02-03 2016-06-08 成都康华生物制品有限公司 一种b型流感嗜血杆菌荚膜多糖的制备方法及联合疫苗
SG11202000224SA (en) 2017-07-18 2020-02-27 Serum Inst Of India Pvt Ltd An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
AU2020277403A1 (en) 2019-05-20 2022-01-06 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
KR20230173114A (ko) 2021-04-20 2023-12-26 케이엠 바이올로직스 가부시키가이샤 6종 혼합 액상 백신 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118963T3 (es) * 1992-05-23 1998-10-01 Smithkline Beecham Biolog Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
JP3280675B2 (ja) * 1996-07-02 2002-05-13 コノート ラボラトリーズ リミテッド 多価ｄｔｐポリオワクチン

Also Published As

Publication number Publication date
ES2257769T3 (es) 2006-08-01
DE69735191T2 (de) 2006-10-05
PT1028750E (pt) 2006-05-31
DK1028750T3 (da) 2006-05-22
AU4707097A (en) 1999-04-05
CA2303105A1 (en) 1999-03-25
EP1028750A1 (de) 2000-08-23
EP1028750B1 (de) 2006-02-01
WO1999013906A1 (en) 1999-03-25
ATE316797T1 (de) 2006-02-15
BR9714980A (pt) 2001-11-06

Similar Documents

Publication Publication Date Title
DE69735191D1 (de) Verfahren zur Herstellung multivalenter Impfstoffe
DE69736709D1 (de) Vielwertige dtp-polio-impfstoffe
HU1000593D0 (en) Vaccine compositions
LU91658I2 (fr) Vaccin combiné diphtérique, tétanique, coquelucheux, hépatite B, poliomyélitique et Haemophilus influenzae type B conjugué (INFANRIX HEXA®)
RU2009105117A (ru) Композиции, включающие антигены neisseria meningitidis из серогрупп в и с, и дополнительный антиген
PL1835939T3 (pl) Skoniugowane szczepionki przeciwko meningokokom
PL1740217T3 (pl) Szczepienie koniugatem meningokokowym
CA2277141A1 (en) Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this procedure
UA27754C2 (uk) Комбінована педіатрична вакцина, спосіб одночасної комбінованої вакцинації
AU2001269569A1 (en) Quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis surface antigen, and preparation method thereof
WO2000051633A3 (en) MULTI-COMPONENT VACCINE COMPRISING AT LEAST THREE ANTIGENS TO PROTECT AGAINST DISEASE CAUSED BY $i(HAEMOPHILUS INFLUENZAE)
DE60033291D1 (de) Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden
GB9611501D0 (en) Vaccine compositions

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI PASTEUR MSD, LYON, FR

8364 No opposition during term of opposition